DOI: 10.36347/sjams.2019.v07i05.035

Pages: 1864-1869

Background: Benign prostatic hyperplasia (BPH) is one of the most common disorders seen in elderly men and is associated with lower urinary tract symptoms (LUTS). This study compared the efficacy of tadalafil, alfuzosin and their combination in the treatment of LUTS associated with BPH. Methods: This was a randomised open-label, comparative study conducted between April 2018 and March 2019, which included men with <60 years of age diagnosed with LUTS associated with BPH with International Prostate Symptom Score (IPSS) more than 8. Patients were randomised into three groups to receive alfuzosin SR 10 mg once-daily (group A); tadalafil 5mg once-daily (group B) or alfuzosin plus tadalafil (group C).Prostate volume, post-void residual (PVR) volume, IPSS, and maximum urinary flow rate (Qmax) were evaluated. Results: A total of 121 patients were included in the study and 94 patients who completed the study were included in the analysis. Demographics and baseline characteristics were comparable between the groups. Patients from group C showed greater percent change (24.79%) in lowering the mean prostate volume. There was a significant (p=0.001) decrease in the IPSS score from baseline at 24 weeks in all three groups; however, the percentage change was higher (35.54%) in group C than group A (24.5%) and B (18.14%). There was a significant improvement in PVR, IIEF in all groups; however, improvements were better in group C. Conclusion: The combination therapy has shown improvement in PVR, IIEF score than tadalafil or alfuzosin alone.